ANIX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases...

Stats
Today's Volume	250 303
Average Volume	118 485
Market Cap	95.06M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.110 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.76
ATR14	$0.0160 (0.54%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Titterton Lewis H Jr	Buy	15 009	Common Stock
2024-03-15	Baskies Arnold M	Buy	10 000	Common Stock
2024-03-15	Kumar Amit	Buy	30 000	Common Stock
2024-01-12	Baskies Arnold M	Buy	25 000	Employee Stock Option (Right to Buy)
2024-01-12	Gottschalk Emily	Buy	25 000	Employee Stock Option (Right to Buy)

INSIDER POWER
60.86
Last 100 transactions
Buy: 11 656 359 \| Sell: 3 491 117

Volume Correlation

Long: -0.21 (neutral)

Short: -0.45 (neutral)

Signal:(39.693) Neutral

Anixa Biosciences Inc Correlation

10 Most Positive Correlations
TCON	0.862
AFMD	0.862
TECH	0.859
UTMD	0.856
TOUR	0.855
CDMO	0.855
HSIC	0.854
XRAY	0.854
ATXI	0.851
INFI	0.851

10 Most Negative Correlations
TYHT	-0.869
NUVL	-0.866
TLND	-0.853
JUPW	-0.852
NAAC	-0.851
HERA	-0.851
HERAU	-0.85
SVFA	-0.85
CPAQ	-0.85
VPCB	-0.848

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Anixa Biosciences Inc Correlation - Currency/Commodity

0.63
( weak )

0.56
( weak )

0.00
( neutral )

0.68
( moderate )

-0.06
( neutral )

-0.27
( neutral )

Anixa Biosciences Inc Financials

Annual	2023
Revenue:	$210 000
Gross Profit:	$49 000.00 (23.33 %)
EPS:	$-0.320

Q1	2024
Revenue:	$0
Gross Profit:	$-13 000.00 (0.00 %)
EPS:	$-0.100

Q4	2023
Revenue:	$156 000
Gross Profit:	$144 000 (92.31 %)
EPS:	$-0.0865

Q3	2023
Revenue:	$0
Gross Profit:	$-11 000.00 (0.00 %)
EPS:	$-0.0811

Financial Reports:

No articles found.

Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.